Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Proscavax |
Synonyms | |
Therapy Description |
Proscavax is a cancer vaccine comprising prostate specific antigen (PSA), IL-2, and GM-CSF, which potentially enhances immune response against tumor cells expressing PSA, leading to reduced tumor cell growth (NCI Drug Dictionary). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Proscavax | PSA/IL-2/GM-CSF Vaccine|Prostatac | Proscavax is a cancer vaccine comprising prostate specific antigen (PSA), IL-2, and GM-CSF, which potentially enhances immune response against tumor cells expressing PSA, leading to reduced tumor cell growth (NCI Drug Dictionary). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03579654 | Phase II | Proscavax | Study of Proscavax Vaccine in Patients With Localized Prostate Cancer vs Active Surveillance | Unknown status | USA | 0 |